Attovia priced an upsized IPO to raise $298 million, with net proceeds expected to fund two large Phase 2 trials starting in early 2027. The company sold 17 million shares at $17 each, above an earlier proposed range, increasing total capital raised to support development of ATTO-1310. ATTO-1310 is an engineered biologic designed to block IL-31, with planned evaluations across chronic pruritic conditions including chronic pruritus of unknown origin, high-itch atopic dermatitis, cholestatic pruritus in primary biliary cholangitis, and uremic pruritus in chronic kidney disease. Attovia said initial Phase Ib data showed rapid, deep itch relief and consistent lesion control, and it plans to build on its ATTOBODY platform licensed from Alamar Biosciences. The IPO is also positioned as adding to a broader rebound in large biotech IPO activity.